<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">Cerebral vasospasm</z:e>, a recognized complication of aneurysmal <z:hpo ids='HP_0002138'>subarachnoid haemorrhage</z:hpo>, can lead to delayed ischaemic neurological deficit, and <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The systematic administration of nimodipine confers a modest but real benefit against delayed ischaemic damage </plain></SENT>
<SENT sid="2" pm="."><plain>When vasospasm occurs, triple-H therapy (<z:e sem="disease" ids="C0546817" disease_type="Disease or Syndrome" abbrv="">hypervolaemia</z:e>, <z:hpo ids='HP_0000822'>hypertension</z:hpo>, and haemodilution) has long been advocated in order to increase flow, but its usefulness remains unclear </plain></SENT>
<SENT sid="3" pm="."><plain>Cardiac output optimization using inotropic drugs might also be considered in selected patients </plain></SENT>
<SENT sid="4" pm="."><plain>In practice, only correction of volume <z:mpath ids='MPATH_63'>depletion</z:mpath> and induced <z:hpo ids='HP_0000822'>hypertension</z:hpo> (after <z:hpo ids='HP_0002617'>aneurysm</z:hpo> has been secured) can be recommended </plain></SENT>
<SENT sid="5" pm="."><plain>In addition, according to phase II randomized trials, promising new treatments for vasospasm or its ischaemic complications include <z:chebi fb="0" ids="32599">magnesium sulfate</z:chebi>, the selective <z:chebi fb="0" ids="51452">endothelin A-receptor antagonist</z:chebi> clazosentan, and <z:chebi fb="0" ids="35664">statins</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>The simple and safe profile of prophylactic use of <z:chebi fb="0" ids="35664">statins</z:chebi> appears particularly attractive </plain></SENT>
<SENT sid="7" pm="."><plain>However, <z:hpo ids='HP_0000001'>all</z:hpo> these potential candidates need further validation through (on-going) clinical phase III trials </plain></SENT>
</text></document>